Background Fatigue is one of the most disabling symptoms in primary Sjogren’s syndrome (pSS) and it significantly impacts patient’s quality of life[1]. However, the cause of this symptom remains ...

Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...

Background Anti-drug antibodies (ADA) to rituximab (RTX) have been reported to a limited extent in rheumatoid arthritis (RA,4%–11%) and in multiple sclerosis (MS ...

Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...

Background An important but often insufficient aspect of care in people with inflammatory arthritis (IA) is empowering patients to acquire a good understanding of their disease and building their ...

1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...

1 Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany 2 Max Delbrück Center for ...

Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent ...

Correspondence to Professor Mary K Crow, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021, USA; crowm{at}hss.edu Research elucidating the pathogenesis of ...

Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...

Correspondence to Professor Ian N Bruce, Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, ...

Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...